$ABCL
AbCellera Biologics Inc. Stock $abcl

$abcl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000170305724000019 Filed on February 20, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$9.954M	$9.179M	$38.03M
YoY Change	-18.36%	-57.4%	-92.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$20.72M	$19.07M	$75.18M
YoY Change	9.58%	21.44%	12.62%
% of Gross Profit
Research & Development	$39.29M	$48.62M	$175.7M
YoY Change	-25.38%	72.14%	62.83%
% of Gross Profit
Depreciation & Amortization	$3.200M	$7.495M	$12.80M
YoY Change	10.34%	-45.64%	42.22%
% of Gross Profit
Operating Expenses	$64.85M	$75.23M	$275.2M
YoY Change	-15.85%	26.82%	2.35%
Operating Profit	-$54.89M		-$237.2M
YoY Change	-15.38%		-209.56%
Interest Expense	$10.40M	$10.97M	$46.15M
YoY Change	6.58%	-8.85%	283.47%
% of Operating Profit
Other Income/Expense, Net	$12.15M	$6.482M	$63.18M
YoY Change	-27.38%	-214.36%	179.7%
Pretax Income	-$42.75M	-$48.60M	-$174.0M
YoY Change	-11.22%	54.72%	-172.79%
Income Tax	-$2.137M	-$1.452M	-$27.63M
% Of Pretax Income
Net Earnings	-$40.61M	-$47.15M	-$146.4M
YoY Change	1.25%	57.73%	-192.35%
Net Earnings / Revenue	-407.98%	-513.67%	-385.0%
Basic Earnings Per Share	-$0.14		-$0.51
Diluted Earnings Per Share	-$0.14	-$0.16	-$0.51
COMMON SHARES
Basic Shares Outstanding	292.8M shares	290.2M shares	289.2M shares
Diluted Shares Outstanding	292.7M shares		289.2M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$698.0M	$760.6M	$760.6M
YoY Change	261.64%	39.58%	96.77%
Cash & Equivalents	$123.6M	52.20M cads	$133.3M
Short-Term Investments	$574.5M	$627.3M	$627.3M
Other Short-Term Assets	$56.51M	$55.81M	$45.91M
YoY Change	-43.01%	-25.99%	34.78%
Inventory	$738.0K	$1.107M	$1.107M
Prepaid Expenses
Receivables	$34.42M	$30.59M	$30.59M
Other Receivables	$34.36M	$33.79M	$33.79M
Total Short-Term Assets	$813.9M	$872.0M	$872.0M
YoY Change	-13.47%	-14.97%	-14.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$306.1M	$287.7M	$287.7M
YoY Change	31.26%	32.42%	32.42%
Goodwill	$47.81M	$47.80M
YoY Change	0.0%	-0.01%
Intangibles	$118.7M	$120.4M
YoY Change	-7.85%	-8.42%
Long-Term Investments	$71.59M	$65.94M	$98.24M
YoY Change	24.33%	-9.08%	35.46%
Other Assets	$104.9M	$94.24M	$61.94M
YoY Change	16.79%	103.41%	33.7%
Total Long-Term Assets	$649.1M	$616.1M	$616.1M
YoY Change	16.49%	19.54%	19.54%
TOTAL ASSETS
Total Short-Term Assets	$813.9M	$872.0M	$872.0M
Total Long-Term Assets	$649.1M	$616.1M	$616.1M
Total Assets	$1.463B	$1.488B	$1.488B
YoY Change	-2.32%	-3.43%	-3.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.91M	$25.51M	$25.51M
YoY Change	53.15%	72.03%	72.03%
Accrued Expenses	$8.378M	$13.87M	$13.87M
YoY Change	42.77%		148.34%
Deferred Revenue	$10.57M	$18.96M
YoY Change	-10.52%	-12.28%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$104.9M	$119.0M	$119.0M
YoY Change	17.07%	0.59%	0.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.735M	$5.906M	$186.2M
YoY Change	93.62%	91.38%	19.23%
Total Long-Term Liabilities	$228.3M	$216.8M	$186.2M
YoY Change	14.25%	14.5%	19.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$104.9M	$119.0M	$119.0M
Total Long-Term Liabilities	$228.3M	$216.8M	$186.2M
Total Liabilities	$333.2M	$335.8M	$335.8M
YoY Change	15.12%	9.15%	9.15%
SHAREHOLDERS EQUITY
Retained Earnings	$239.2M	$279.8M
YoY Change	-38.05%	-34.35%
Common Stock	$892.6M	$874.3M
YoY Change	8.26%	8.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.130B	$1.152B	$1.152B
YoY Change
Total Liabilities & Shareholders Equity	$1.463B	$1.488B	$1.488B
YoY Change	-2.32%	-3.43%	-3.43%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$40.61M	-$47.15M	-$146.4M
YoY Change	1.25%	57.73%	-192.35%
Depreciation, Depletion And Amortization	$3.200M	$7.495M	$12.80M
YoY Change	10.34%	-45.64%	42.22%
Cash From Operating Activities	-$41.71M	-$19.58M	-$43.88M
YoY Change	-5.34%	-163.33%	-115.82%
INVESTING ACTIVITIES
Capital Expenditures	$24.14M	$14.41M	$76.95M
YoY Change	61.11%	16.85%	8.9%
Acquisitions			$0.00
YoY Change
Other Investing Activities	$54.05M	-$9.901M	-$143.6M
YoY Change	-140.15%	109.19%	-48.71%
Cash From Investing Activities	$29.91M	-$24.31M	-$221.1M
YoY Change	-119.99%	42.46%	-37.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.831M	3.756M	$10.36M
YoY Change	-718.12%	976.22%	-736.12%
NET CHANGE
Cash From Operating Activities	-$41.71M	-19.58M	-$43.88M
Cash From Investing Activities	$29.91M	-24.31M	-$221.1M
Cash From Financing Activities	$2.831M	3.756M	$10.36M
Net Change In Cash	-$9.748M	-40.13M	-$254.0M
YoY Change	-94.98%	-382.64%	193.72%
FREE CASH FLOW
Cash From Operating Activities	-$41.71M	-$19.58M	-$43.88M
Capital Expenditures	$24.14M	$14.41M	$76.95M
Free Cash Flow	-$65.85M	-$33.98M	-$120.8M
YoY Change	11.52%	-282.89%	-158.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41848000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14451000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27843000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	170790000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	268913000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	275232000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	204413000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	216511000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-237207000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	16079000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	42247000	usd
CY2023	abcl	Grants And Incentives GrantsAndIncentives	14155000	usd
CY2022Q4	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	9064000	usd
CY2022Q4	abcl	Materials And Supplies Current MaterialsAndSuppliesCurrent	1532000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001703057
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.abcellera.com/20231231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.abcellera.com/20231231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization
CY2022	us-gaap	Impairment Of Intangible Asset Indefinite Lived Excluding Goodwill Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#IntangibleAssetsNetExcludingGoodwill
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39781
CY2023	dei	Entity Registrant Name EntityRegistrantName	AbCellera Biologics Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2215 Yukon Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V5Y 0A1
CY2023	dei	City Area Code CityAreaCode	604
CY2023	dei	Local Phone Number LocalPhoneNumber	559-9005
CY2023	dei	Security12b Title Security12bTitle	Common shares, no par value per share
CY2023	dei	Trading Symbol TradingSymbol	ABCL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1463836452	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	292782152	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	85
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Vancouver, Canada
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	386535000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133320000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	499950000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	627265000	usd
CY2022Q4	abcl	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	886485000	usd
CY2023Q4	abcl	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	760585000	usd
CY2022Q4	abcl	Accounts And Accrued Receivable Current AccountsAndAccruedReceivableCurrent	38593000	usd
CY2023Q4	abcl	Accounts And Accrued Receivable Current AccountsAndAccruedReceivableCurrent	30590000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	75413000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	55810000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1025491000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	871985000	usd
CY2022Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	217255000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	287696000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131502000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120425000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	47806000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	47806000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	72522000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	65938000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	46331000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	94244000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	515416000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	616109000	usd
CY2022Q4	us-gaap	Assets Assets	1540907000	usd
CY2023Q4	us-gaap	Assets Assets	1488094000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	52497000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	49580000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	44211000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	50475000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21612000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18958000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118320000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	119013000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76675000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71222000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	19516000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8195000	usd
CY2022Q4	abcl	Deferred Government Assistance Noncurrent DeferredGovernmentAssistanceNoncurrent	40801000	usd
CY2023Q4	abcl	Deferred Government Assistance Noncurrent DeferredGovernmentAssistanceNoncurrent	95915000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16054000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4913000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33178000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	30612000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3086000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5906000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	189310000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	216763000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	307630000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	335776000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	286851595	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	286851595	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	290824970	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	290824970	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	734365000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	753199000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74118000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	121052000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1391000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1720000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	426185000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	279787000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1152318000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1540907000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1488094000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	375203000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	485424000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38025000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	45516000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	66436000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62062000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107879000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	175658000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6913000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11270000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14180000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55485000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60999000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	24395000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	3330000	usd
CY2021	abcl	Grants And Incentives GrantsAndIncentives	17486000	usd
CY2022	abcl	Grants And Incentives GrantsAndIncentives	10554000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6080000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4045000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6776000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14736000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22588000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	63178000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	219149000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	239099000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-174029000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65685000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80580000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27631000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	158519000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-146398000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-329000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	275763745	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	285056606	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	318294236	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	314827255	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	289166486	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	830508000	usd
CY2021	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	6566000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29240000	usd
CY2021	abcl	Adjustments To Additional Paid In Capital Reclassification Of Liability Classified Options AdjustmentsToAdditionalPaidInCapitalReclassificationOfLiabilityClassifiedOptions	5675000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	280000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	153464000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1025733000	usd
CY2022	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	1215000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49481000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1671000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	158519000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1233277000	usd
CY2023	abcl	Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised	1584000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64184000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-329000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-146398000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1152318000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	153464000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	158519000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-146398000	usd
CY2021	us-gaap	Depreciation Depreciation	4403000	usd
CY2022	us-gaap	Depreciation Depreciation	8953000	usd
CY2023	us-gaap	Depreciation Depreciation	12758000	usd
CY2021	abcl	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	10062000	usd
CY2022	abcl	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	18890000	usd
CY2023	abcl	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	11637000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2785000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5259000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6499000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	30646000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	49481000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	64183000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2018000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2114000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1960000	usd
CY2021	abcl	Change In Fair Value Of Contingent Consideration And Investments ChangeInFairValueOfContingentConsiderationAndInvestments	2284000	usd
CY2022	abcl	Change In Fair Value Of Contingent Consideration And Investments ChangeInFairValueOfContingentConsiderationAndInvestments	3091000	usd
CY2023	abcl	Change In Fair Value Of Contingent Consideration And Investments ChangeInFairValueOfContingentConsiderationAndInvestments	-8018000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1286000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5456000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-277000	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	37386000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	22715000	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	45933000	usd
CY2021	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-59864000	usd
CY2022	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-129171000	usd
CY2023	abcl	Increase Decrease In Accrued Royalties Receivable IncreaseDecreaseInAccruedRoyaltiesReceivable	-9273000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-13530000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-88609000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9599000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	30464000	usd
CY2021	abcl	Increase Decrease In Accounts Payable And Other Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesExcludingRoyaltiesPayable	-3237000	usd
CY2022	abcl	Increase Decrease In Accounts Payable And Other Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesExcludingRoyaltiesPayable	-2094000	usd
CY2023	abcl	Increase Decrease In Accounts Payable And Other Liabilities Excluding Royalties Payable IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesExcludingRoyaltiesPayable	-15104000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	8624000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6183000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13976000	usd
CY2021	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-30718000	usd
CY2022	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-9264000	usd
CY2023	abcl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	-39521000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3381000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1375000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-8980000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	244584000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	277360000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43877000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58452000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70660000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76947000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	560000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	274710000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	763982000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1021510000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	27608000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	510631000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	910937000	usd
CY2021	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	32621000	usd
CY2022	abcl	Proceeds From Receipt Of Grant Funding ProceedsFromReceiptOfGrantFunding	16434000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	11457000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	17534000	usd
CY2022	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	17369000	usd
CY2023	abcl	Payments To Acquire Long Term Investments And Other Assets PaymentsToAcquireLongTermInvestmentsAndOtherAssets	44649000	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	30323000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	25679000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	13690000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-332247000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-352625000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-221108000	usd
CY2021	abcl	Repayment Of Liability For In Licensing Agreement And Contingent Consideration RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration	9373000	usd
CY2022	abcl	Repayment Of Liability For In Licensing Agreement And Contingent Consideration RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration	4383000	usd
CY2023	abcl	Repayment Of Liability For In Licensing Agreement And Contingent Consideration RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration	1234000	usd
CY2021	abcl	Proceeds From Liabilities And Exercise Of Stock Options ProceedsFromLiabilitiesAndExerciseOfStockOptions	5487000	usd
CY2022	abcl	Proceeds From Liabilities And Exercise Of Stock Options ProceedsFromLiabilitiesAndExerciseOfStockOptions	2755000	usd
CY2023	abcl	Proceeds From Liabilities And Exercise Of Stock Options ProceedsFromLiabilitiesAndExerciseOfStockOptions	11590000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3886000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1628000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10356000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1425000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	589000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92974000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-86492000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-254040000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	594116000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	501142000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414650000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	501142000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	414650000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	160610000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3115000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2290000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	501142000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	411535000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158320000	usd
CY2021	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	5397000	usd
CY2022	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	5868000	usd
CY2023	abcl	Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable	13625000	usd
CY2021	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	36638000	usd
CY2022	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	50694000	usd
CY2023	abcl	Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation	1199000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Nature of operations<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs and to develop its own pipeline of future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together</span>.
CY2021Q4	abcl	Company Contributed Segregated Account Representing Loss CompanyContributedSegregatedAccountRepresentingLoss	25000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div>The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the fair value of acquired intangible assets, and contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.
CY2022Q4	us-gaap	Cash Cash	126200000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	260300000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	28100000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000000	usd
CY2022Q4	abcl	Restricted Cash Current Other Current Assets RestrictedCashCurrentOtherCurrentAssets	2200000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	usd
CY2023Q4	us-gaap	Cash Cash	127500000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5800000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	27300000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	25000000	usd
CY2023Q4	abcl	Restricted Cash Current Other Current Assets RestrictedCashCurrentOtherCurrentAssets	1600000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	700000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	500000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1700000	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2100000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	18500000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	32300000	usd
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	1700000	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	0	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	1800000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	275763745	shares
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.50
CY2022Q4	abcl	Deferred Compensation Share Based Arrangements Liability Classified Noncurrent Outstanding DeferredCompensationShareBasedArrangementsLiabilityClassifiedNoncurrentOutstanding	0	shares
CY2023Q4	abcl	Deferred Compensation Share Based Arrangements Liability Classified Noncurrent Outstanding DeferredCompensationShareBasedArrangementsLiabilityClassifiedNoncurrentOutstanding	0	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	285056606	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	289166486	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	153464000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	158519000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-146398000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	25600000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	153464000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	158519000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-146398000	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	275763745	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	285056606	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	289166486	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	42530491	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	29770649	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	318294236	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	314827255	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	289166486	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.50
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	908409	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11824006	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50087088	shares
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	64817000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	33792000	usd
CY2023Q4	abcl	Prepaid Expense And Other Current PrepaidExpenseAndOtherCurrent	20911000	usd
CY2023Q4	abcl	Materials And Supplies Current MaterialsAndSuppliesCurrent	1107000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	75413000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	55810000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	80838000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	73141000	usd
CY2022Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsBeforeAccumulatedDepreciationAndAmortization	235730000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsBeforeAccumulatedDepreciationAndAmortization	318304000	usd
CY2022Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAccumulatedDepreciationAndAmortization	18475000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAccumulatedDepreciationAndAmortization	30608000	usd
CY2022Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	217255000	usd
CY2023Q4	abcl	Property Plant And Equipment And Operating Lease Right Of Use Assets After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetsAfterAccumulatedDepreciationAndAmortization	287696000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	91000000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	13700000	usd
CY2021	us-gaap	Depreciation Depreciation	4400000	usd
CY2022	us-gaap	Depreciation Depreciation	9000000	usd
CY2023	us-gaap	Depreciation Depreciation	12800000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	154583000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23081000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131502000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	155143000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	34718000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120425000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10100000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10500000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11600000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	8400000	usd
CY2022	abcl	Impairment Of Intangible Assets Finite Lived Net Of Deferred Income Tax ImpairmentOfIntangibleAssetsFiniteLivedNetOfDeferredIncomeTax	6300000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4912000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4297000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4297000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4297000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4297000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22100000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	47800000	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2023	abcl	Number Of Joint Ventures NumberOfJointVentures	2	jointventure
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	900000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1800000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	14828000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	25509000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5583000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6158000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6454000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7707000	usd
CY2022Q4	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	6285000	usd
CY2023Q4	abcl	Deferred Grant Funding Current DeferredGrantFundingCurrent	7112000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	19347000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3094000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	52497000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	49580000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	286851595	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	286851595	shares
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	290824970	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	290824970	shares
CY2023	us-gaap	Dividends Cash DividendsCash	0	usd
CY2021Q1	abcl	Conversion Of Liability Classified Options To Equity ConversionOfLiabilityClassifiedOptionsToEquity	5700000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30646000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49481000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	64184000	usd
CY2023	us-gaap	Dividends Dividends	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	41128000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27153000	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4700000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	11500000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	17000000	usd
CY2022	abcl	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	Government Contribution 1
CY2022	abcl	Government Assistance Accounts Receivable Current GovernmentAssistanceAccountsReceivableCurrent	6927000	usd
CY2022	abcl	Government Assistance Non Repayable Current GovernmentAssistanceNonRepayableCurrent	5100000	usd
CY2022	abcl	Government Assistance Conditionally Repayable Current GovernmentAssistanceConditionallyRepayableCurrent	1185000	usd
CY2022	abcl	Government Assistance Repayable Current GovernmentAssistanceRepayableCurrent	0	usd
CY2022	abcl	Government Assistance Amount Current GovernmentAssistanceAmountCurrent	6285000	usd
CY2022	abcl	Government Assistance Accounts Receivable Long Term GovernmentAssistanceAccountsReceivableLongTerm	0	usd
CY2022	abcl	Government Assistance Non Repayable Long Term GovernmentAssistanceNonRepayableLongTerm	9764000	usd
CY2022	abcl	Government Assistance Conditionally Repayable Long Term GovernmentAssistanceConditionallyRepayableLongTerm	31037000	usd
CY2022	abcl	Government Assistance Repayable Long Term GovernmentAssistanceRepayableLongTerm	0	usd
CY2022	abcl	Government Assistance Amount Noncurrent GovernmentAssistanceAmountNoncurrent	40801000	usd
CY2022	abcl	Government Assistance Weighted Average Life GovernmentAssistanceWeightedAverageLife	P8Y
CY2023	abcl	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	Government Contribution 1
CY2023	abcl	Government Assistance Accounts Receivable GovernmentAssistanceAccountsReceivable	36051000	usd
CY2023	abcl	Government Assistance Non Repayable GovernmentAssistanceNonRepayable	14811000	usd
CY2023	abcl	Government Assistance Conditionally Repayable GovernmentAssistanceConditionallyRepayable	71796000	usd
CY2023	abcl	Government Assistance Repayable GovernmentAssistanceRepayable	16420000	usd
CY2023	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	103027000	usd
CY2023	abcl	Government Assistance Accounts Receivable Current GovernmentAssistanceAccountsReceivableCurrent	26945000	usd
CY2023	abcl	Government Assistance Non Repayable Current GovernmentAssistanceNonRepayableCurrent	4450000	usd
CY2023	abcl	Government Assistance Conditionally Repayable Current GovernmentAssistanceConditionallyRepayableCurrent	2662000	usd
CY2023	abcl	Government Assistance Repayable Current GovernmentAssistanceRepayableCurrent	0	usd
CY2023	abcl	Government Assistance Amount Current GovernmentAssistanceAmountCurrent	7112000	usd
CY2023	abcl	Government Assistance Accounts Receivable Long Term GovernmentAssistanceAccountsReceivableLongTerm	9106000	usd
CY2023	abcl	Government Assistance Non Repayable Long Term GovernmentAssistanceNonRepayableLongTerm	10361000	usd
CY2023	abcl	Government Assistance Conditionally Repayable Long Term GovernmentAssistanceConditionallyRepayableLongTerm	69134000	usd
CY2023	abcl	Government Assistance Repayable Long Term GovernmentAssistanceRepayableLongTerm	16420000	usd
CY2023	abcl	Government Assistance Amount Noncurrent GovernmentAssistanceAmountNoncurrent	95915000	usd
CY2022	abcl	Government Assistance Weighted Average Life GovernmentAssistanceWeightedAverageLife	P8Y
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-27707000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	219149000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	239099000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-174029000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	211471000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	279771000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-146322000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	7678000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-40672000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	60498000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	81392000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-29591000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	7248000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1300000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	67746000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	82692000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-29591000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1342000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2322000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	4526000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-719000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-4434000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2566000	usd
CY2021	abcl	Deferred And Other Income Tax Expense Benefit DeferredAndOtherIncomeTaxExpenseBenefit	-2061000	usd
CY2022	abcl	Deferred And Other Income Tax Expense Benefit DeferredAndOtherIncomeTaxExpenseBenefit	-2112000	usd
CY2023	abcl	Deferred And Other Income Tax Expense Benefit DeferredAndOtherIncomeTaxExpenseBenefit	1960000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65685000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80580000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27631000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	67746000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	82692000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-29591000	usd
CY2021	abcl	Deferred And Other Income Tax Expense Benefit DeferredAndOtherIncomeTaxExpenseBenefit	-2061000	usd
CY2022	abcl	Deferred And Other Income Tax Expense Benefit DeferredAndOtherIncomeTaxExpenseBenefit	-2112000	usd
CY2023	abcl	Deferred And Other Income Tax Expense Benefit DeferredAndOtherIncomeTaxExpenseBenefit	1960000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65685000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80580000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27631000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	219149000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	239099000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-174029000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	59170000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	64557000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-46988000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	7007000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	11710000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	17081000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5007000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8318000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11485000	usd
CY2021	abcl	Income Tax Reconciliation Change In Tax Rate Differential IncomeTaxReconciliationChangeInTaxRateDifferential	0	usd
CY2022	abcl	Income Tax Reconciliation Change In Tax Rate Differential IncomeTaxReconciliationChangeInTaxRateDifferential	1911000	usd
CY2023	abcl	Income Tax Reconciliation Change In Tax Rate Differential IncomeTaxReconciliationChangeInTaxRateDifferential	1042000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	3529000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-344000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4809000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5908000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	7428000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-691000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	285000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-395000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65685000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80580000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27631000	usd
CY2022Q4	abcl	Deferred Tax Assets Government Contributions DeferredTaxAssetsGovernmentContributions	7695000	usd
CY2023Q4	abcl	Deferred Tax Assets Government Contributions DeferredTaxAssetsGovernmentContributions	4389000	usd
CY2022Q4	abcl	Deferred Tax Assets Financing Fee DeferredTaxAssetsFinancingFee	4827000	usd
CY2023Q4	abcl	Deferred Tax Assets Financing Fee DeferredTaxAssetsFinancingFee	3092000	usd
CY2022Q4	abcl	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	17355000	usd
CY2023Q4	abcl	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	17211000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	6042000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	21241000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5054000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7256000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1807000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	24303000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4696000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3725000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47476000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	81217000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8450000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	17303000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	32682000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	30117000	usd
CY2022Q4	abcl	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	16687000	usd
CY2023Q4	abcl	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	16569000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	4094000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	13186000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	61913000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	77175000	usd
CY2022Q4	abcl	Deferred Tax Liabilities Net Of Deferred Tax Assets Gross DeferredTaxLiabilitiesNetOfDeferredTaxAssetsGross	14437000	usd
CY2023Q4	abcl	Deferred Tax Liabilities Net Of Deferred Tax Assets Gross DeferredTaxLiabilitiesNetOfDeferredTaxAssetsGross	-4042000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13411000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33840000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	27848000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	29798000	usd
CY2022Q4	abcl	Deferred Tax Assets Net Of Valuation Allowance By Legal Entity DeferredTaxAssetsNetOfValuationAllowanceByLegalEntity	5330000	usd
CY2023Q4	abcl	Deferred Tax Assets Net Of Valuation Allowance By Legal Entity DeferredTaxAssetsNetOfValuationAllowanceByLegalEntity	814000	usd
CY2022Q4	abcl	Deferred Tax Liability Goss By Legal Entity DeferredTaxLiabilityGossByLegalEntity	33178000	usd
CY2023Q4	abcl	Deferred Tax Liability Goss By Legal Entity DeferredTaxLiabilityGossByLegalEntity	30612000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	27848000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	29798000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	10200000	usd
CY2023	abcl	Non Capital Loss And Investment Tax Credits Backup Period NonCapitalLossAndInvestmentTaxCreditsBackupPeriod	P3Y
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	18200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	19400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	19400000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5583000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6158000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76675000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71222000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	82258000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	77380000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9807000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9694000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9280000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8248000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8270000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	58818000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	3700000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	7100000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	9500000	usd
CY2021	us-gaap	Variable Lease Payment VariableLeasePayment	400000	usd
CY2022	us-gaap	Variable Lease Payment VariableLeasePayment	1800000	usd
CY2023	us-gaap	Variable Lease Payment VariableLeasePayment	1100000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P0Y4M24D
CY2021	us-gaap	Royalty Expense RoyaltyExpense	45500000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	66400000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.10
CY2023Q4	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	3200000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	2000000	usd
CY2022Q4	abcl	Accounts And Accrued Royalty Receivable Amounts Due Number Of Customers AccountsAndAccruedRoyaltyReceivableAmountsDueNumberOfCustomers	21	customer
CY2023Q4	abcl	Accounts And Accrued Royalty Receivable Amounts Due Number Of Customers AccountsAndAccruedRoyaltyReceivableAmountsDueNumberOfCustomers	10	customer
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133300000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	27300000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	627300000	usd
CY2023Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.0100
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44900000	cad
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52200000	cad
CY2023Q4	abcl	Business Acquisitions Purchase Price Allocation Adjustments BusinessAcquisitionsPurchasePriceAllocationAdjustments	0	usd

Files In Submission

Name	View Source	Status
0001703057-24-000019-index-headers.html	Edgar Link	pending
0001703057-24-000019-index.html	Edgar Link	pending
0001703057-24-000019.txt	Edgar Link	pending
0001703057-24-000019-xbrl.zip	Edgar Link	pending
abcl-20221231xexx311.htm	Edgar Link	pending
abcl-20221231xexx312.htm	Edgar Link	pending
abcl-20221231xexx321.htm	Edgar Link	pending
abcl-20221231xexx322.htm	Edgar Link	pending
abcl-20231231.htm	Edgar Link	pending
abcl-20231231.xsd	Edgar Link	pending
abcl-20231231_g1.jpg	Edgar Link	pending
abcl-20231231_g2.jpg	Edgar Link	pending
abcl-20231231_g3.jpg	Edgar Link	pending
abcl-20231231_g4.jpg	Edgar Link	pending
abcl-20231231_g5.jpg	Edgar Link	pending
exhibit1017abcellerabcco.htm	Edgar Link	pending
exhibit1017abcellerabcco001.jpg	Edgar Link	pending
exhibit1017abcellerabcco002.jpg	Edgar Link	pending
exhibit1017abcellerabcco003.jpg	Edgar Link	pending
exhibit1017abcellerabcco004.jpg	Edgar Link	pending
R14.htm	Edgar Link	pending
abcl-20231231_def.xml	Edgar Link	unprocessable
abcl-20231231_lab.xml	Edgar Link	unprocessable
abcl-20231231_pre.xml	Edgar Link	unprocessable
abcl-20231231_htm.xml	Edgar Link	completed
exhibit1017abcellerabcco005.jpg	Edgar Link	pending
exhibit1017abcellerabcco006.jpg	Edgar Link	pending
exhibit1017abcellerabcco007.jpg	Edgar Link	pending
exhibit1017abcellerabcco008.jpg	Edgar Link	pending
exhibit1017abcellerabcco009.jpg	Edgar Link	pending
exhibit1017abcellerabcco010.jpg	Edgar Link	pending
exhibit1017abcellerabcco011.jpg	Edgar Link	pending
exhibit1017abcellerabcco012.jpg	Edgar Link	pending
exhibit1017abcellerabcco013.jpg	Edgar Link	pending
exhibit1017abcellerabcco014.jpg	Edgar Link	pending
exhibit1017abcellerabcco015.jpg	Edgar Link	pending
exhibit1017abcellerabcco016.jpg	Edgar Link	pending
exhibit1017abcellerabcco017.jpg	Edgar Link	pending
exhibit1017abcellerabcco018.jpg	Edgar Link	pending
exhibit1017abcellerabcco019.jpg	Edgar Link	pending
exhibit1017abcellerabcco020.jpg	Edgar Link	pending
exhibit1017abcellerabcco021.jpg	Edgar Link	pending
exhibit1017abcellerabcco022.jpg	Edgar Link	pending
exhibit1017abcellerabcco023.jpg	Edgar Link	pending
exhibit1017abcellerabcco024.jpg	Edgar Link	pending
exhibit1017abcellerabcco025.jpg	Edgar Link	pending
exhibit1017abcellerabcco026.jpg	Edgar Link	pending
exhibit1017abcellerabcco027.jpg	Edgar Link	pending
exhibit1017abcellerabcco028.jpg	Edgar Link	pending
exhibit1017abcellerabcco029.jpg	Edgar Link	pending
exhibit1017abcellerabcco030.jpg	Edgar Link	pending
exhibit1017abcellerabcco031.jpg	Edgar Link	pending
exhibit1017abcellerabcco032.jpg	Edgar Link	pending
exhibit1017abcellerabcco033.jpg	Edgar Link	pending
exhibit1017abcellerabcco034.jpg	Edgar Link	pending
exhibit1017abcellerabcco035.jpg	Edgar Link	pending
exhibit1017abcellerabcco036.jpg	Edgar Link	pending
exhibit1017abcellerabcco037.jpg	Edgar Link	pending
exhibit1017abcellerabcco038.jpg	Edgar Link	pending
exhibit1017abcellerabcco039.jpg	Edgar Link	pending
exhibit1017abcellerabcco040.jpg	Edgar Link	pending
exhibit1017abcellerabcco041.jpg	Edgar Link	pending
exhibit1017abcellerabcco042.jpg	Edgar Link	pending
exhibit1017abcellerabcco043.jpg	Edgar Link	pending
exhibit1017abcellerabcco044.jpg	Edgar Link	pending
exhibit1017abcellerabcco045.jpg	Edgar Link	pending
exhibit1017abcellerabcco046.jpg	Edgar Link	pending
exhibit1017abcellerabcco047.jpg	Edgar Link	pending
exhibit1017abcellerabcco048.jpg	Edgar Link	pending
exhibit1017abcellerabcco049.jpg	Edgar Link	pending
exhibit1017abcellerabcco050.jpg	Edgar Link	pending
exhibit1017abcellerabcco051.jpg	Edgar Link	pending
exhibit1017abcellerabcco052.jpg	Edgar Link	pending
exhibit1017abcellerabcco053.jpg	Edgar Link	pending
exhibit1017abcellerabcco054.jpg	Edgar Link	pending
exhibit1017abcellerabcco055.jpg	Edgar Link	pending
exhibit1018abcellera813-.htm	Edgar Link	pending
exhibit1018abcellera813-001.jpg	Edgar Link	pending
exhibit1018abcellera813-002.jpg	Edgar Link	pending
exhibit1018abcellera813-003.jpg	Edgar Link	pending
exhibit1018abcellera813-004.jpg	Edgar Link	pending
exhibit1018abcellera813-005.jpg	Edgar Link	pending
exhibit1018abcellera813-006.jpg	Edgar Link	pending
exhibit1018abcellera813-007.jpg	Edgar Link	pending
exhibit1018abcellera813-008.jpg	Edgar Link	pending
exhibit1018abcellera813-009.jpg	Edgar Link	pending
exhibit1018abcellera813-010.jpg	Edgar Link	pending
exhibit1018abcellera813-011.jpg	Edgar Link	pending
exhibit1018abcellera813-012.jpg	Edgar Link	pending
exhibit1018abcellera813-013.jpg	Edgar Link	pending
exhibit1018abcellera813-014.jpg	Edgar Link	pending
exhibit1018abcellera813-015.jpg	Edgar Link	pending
exhibit1018abcellera813-016.jpg	Edgar Link	pending
exhibit1018abcellera813-017.jpg	Edgar Link	pending
exhibit1018abcellera813-018.jpg	Edgar Link	pending
exhibit1018abcellera813-019.jpg	Edgar Link	pending
exhibit1018abcellera813-020.jpg	Edgar Link	pending
exhibit1018abcellera813-021.jpg	Edgar Link	pending
exhibit1018abcellera813-022.jpg	Edgar Link	pending
exhibit1018abcellera813-023.jpg	Edgar Link	pending
exhibit1018abcellera813-024.jpg	Edgar Link	pending
exhibit1018abcellera813-025.jpg	Edgar Link	pending
exhibit1018abcellera813-026.jpg	Edgar Link	pending
exhibit1018abcellera813-027.jpg	Edgar Link	pending
exhibit1018abcellera813-028.jpg	Edgar Link	pending
exhibit1018abcellera813-029.jpg	Edgar Link	pending
exhibit1018abcellera813-030.jpg	Edgar Link	pending
exhibit1018abcellera813-031.jpg	Edgar Link	pending
exhibit1018abcellera813-032.jpg	Edgar Link	pending
exhibit1018abcellera813-033.jpg	Edgar Link	pending
exhibit1018abcellera813-034.jpg	Edgar Link	pending
exhibit1018abcellera813-035.jpg	Edgar Link	pending
exhibit1018abcellera813-036.jpg	Edgar Link	pending
exhibit1018abcellera813-037.jpg	Edgar Link	pending
exhibit1018abcellera813-038.jpg	Edgar Link	pending
exhibit1018abcellera813-039.jpg	Edgar Link	pending
exhibit1018abcellera813-040.jpg	Edgar Link	pending
exhibit1018abcellera813-041.jpg	Edgar Link	pending
exhibit1018abcellera813-042.jpg	Edgar Link	pending
exhibit1018abcellera813-043.jpg	Edgar Link	pending
exhibit1018abcellera813-044.jpg	Edgar Link	pending
exhibit1018abcellera813-045.jpg	Edgar Link	pending
exhibit1018abcellera813-046.jpg	Edgar Link	pending
exhibit1018abcellera813-047.jpg	Edgar Link	pending
exhibit1018abcellera813-048.jpg	Edgar Link	pending
exhibit1018abcellera813-049.jpg	Edgar Link	pending
exhibit1018abcellera813-050.jpg	Edgar Link	pending
exhibit1018abcellera813-051.jpg	Edgar Link	pending
exhibit1018abcellera813-052.jpg	Edgar Link	pending
exhibit1018abcellera813-053.jpg	Edgar Link	pending
exhibit1018abcellera813-054.jpg	Edgar Link	pending
exhibit1018abcellera813-055.jpg	Edgar Link	pending
exhibit1018abcellera813-056.jpg	Edgar Link	pending
exhibit1018abcellera813-057.jpg	Edgar Link	pending
exhibit1018abcellera813-058.jpg	Edgar Link	pending
exhibit1018abcellera813-059.jpg	Edgar Link	pending
exhibit1018abcellera813-060.jpg	Edgar Link	pending
exhibit1018abcellera813-061.jpg	Edgar Link	pending
exhibit1018abcellera813-062.jpg	Edgar Link	pending
exhibit1018abcellera813-063.jpg	Edgar Link	pending
exhibit1018abcellera813-064.jpg	Edgar Link	pending
exhibit1018abcellera813-065.jpg	Edgar Link	pending
exhibit1018abcellera813-066.jpg	Edgar Link	pending
exhibit1018abcellera813-067.jpg	Edgar Link	pending
exhibit1018abcellera813-068.jpg	Edgar Link	pending
exhibit1018abcellera813-069.jpg	Edgar Link	pending
exhibit1018abcellera813-070.jpg	Edgar Link	pending
exhibit1018abcellera813-071.jpg	Edgar Link	pending
exhibit1018abcellera813-072.jpg	Edgar Link	pending
exhibit211.htm	Edgar Link	pending
exhibit211001.jpg	Edgar Link	pending
exhibit231abclconsent-fo.htm	Edgar Link	pending
exhibit231abclconsent-fo001.jpg	Edgar Link	pending
exhibit97-abcelleraxcomp.htm	Edgar Link	pending
exhibit97-abcelleraxcomp001.jpg	Edgar Link	pending
exhibit97-abcelleraxcomp002.jpg	Edgar Link	pending
exhibit97-abcelleraxcomp003.jpg	Edgar Link	pending
exhibit97-abcelleraxcomp004.jpg	Edgar Link	pending
exhibit97-abcelleraxcomp005.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
abcl-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABCL
AbCellera Biologics Inc. Stock $abcl

2024 Q1 Form 10-K Financial Statement

#000170305724000019 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL AbCellera Biologics Inc. Stock $abcl

2024 Q1 Form 10-K Financial Statement

#000170305724000019 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABCL
AbCellera Biologics Inc. Stock $abcl